AHR Agonist
Novel AHR agonist compounds address the need for effective treatments of immune-mediated diseases by activating aryl hydrocarbon receptors to regulate immune responses, providing therapeutic benefits for conditions like psoriasis and atopic dermatitis.
JP2026510183APending Publication Date: 2026-04-02ELI LILLY & CO
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-10-27
- Publication Date
- 2026-04-02
AI Technical Summary
Technical Problem
There is a significant unmet need for alternative, potent, selective, and safer medications for the treatment of immune-mediated diseases (IMDs) such as psoriasis and atopic dermatitis, as current treatments have limited efficacy and few small molecule therapy options.
Method used
Development of novel AHR agonist compounds that activate aryl hydrocarbon receptors (AHRs) to regulate immunological functions, including the suppression of adaptive immune responses, through specific compounds and pharmaceutical compositions.
Benefits of technology
The AHR agonist compounds provide effective treatment options for IMDs by modulating immune responses, offering potential therapeutic benefits for conditions like psoriasis and atopic dermatitis.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026510183000001_ABST
Abstract
This disclosure includes, for example, the following general formula: [Formula 1] Regarding a specific AHR agonist compound having TIFF2026510183000127.tif18128, The present invention relates to a pharmaceutical composition containing the compound, and to a method of using the compound to treat immune-mediated diseases such as psoriasis and atopic dermatitis.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Inhibitors of farnesyl-protein transferase
JP2000502356A
Kinase inhibitors and uses thereof
WO2018213632A1
Aryl hydrocarbon receptor (AHR) agonists and uses thereof
WO2022133480A1